Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus VIRILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus VIRILON.
HALOTESTIN vs VIRILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Category C
Category C
Androgen
Androgen